Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms:

* Cough * Fever * Tired * Sore throat * Difficulty breathing * Respiratory distress * Headache * Loss (or alteration) of smell * Loss (or alteration) of sense of taste * Myalgias * Chills * Subjective fever * Pink sputum (or coughing up blood) * Thoracic pain * Runny nose * Abdominal pain * Nausea * Vomiting * Diarrhea * Constipation * Irritated or watery eyes * Rashes * Other

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sars-CoV-2 Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Influenza Viral Infections Lung Diseases Mononegavirales Infections Mucosal Immunity Nidovirales Infections Paramyxoviridae Infections Pneumonia Pneumonia, Viral Pneumovirus Infections RNA Virus Infections RSV Infection Respiratory Syncytial Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases Virus Shedding

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Geneva University Hospital

Geneva, 1204, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In general good health, as determined by study investigators
All participants must be living in the canton of Geneva or working/studying in the canton of Geneva and living in neighboring communities that are within one hour travelling distance by car.

Exclusion criteria

Inability to provide written consent.
Severely immunocompromised subjects as determined by the study investigator
Treated with inhaled drugs by nasal route within the last month

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

SARS-CoV-2 infectious viral load

Time frame: up to 14 days post symptom onset

Sponsors and collaborators

Lead sponsor

University Hospital, Geneva

Other

Collaborators

ModernaTX, Inc.
University of Geneva, Switzerland

Registry information

Acronym: MIViral

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Apr 3, 2023
Registry last updated: Jan 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed